Other Events. On May 21, 2026, Immix Biopharma, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, as representative of the several underwriters named in Schedule I thereto, pursuant to which the Company agreed to issue and sell, in an underwritten offering (the “Offering”), an aggregate of 16,778,524 shares of its common stock, par value $0.0001 per share (the “Shares”) at a public offering price…

Other Events. On May 21, 2026, the Company announced an update from the Phase 2 NEXICART-2 NXC-201 clinical trial, including that all four MRD-negative relapsed/refractory AL Amyloidosis patients announced by the Company at the ASH 2025 have converted to CR. Of the first 20 patients in NEXICART-2, all MRD-negative patients have converted to CR, increasing the CR rate to 95% (19/20). No relapses have been observed to date for patients who have reached CR, and all CRs were reached within one ye…

Entry into a Material Definitive Agreement. On March 25, 2026, Immix Biopharma, Inc., a Delaware corporation (the “Company”) and Citizens JMP Securities, LLC entered into Amendment No. 1 (“Amendment No. 1”) to that certain At The Market Offering Agreement, dated June 3, 2025 (the “Sales Agreement”), pursuant to which the Company may offer and sell, from time to time, at its option, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), through Citizens JMP Sec…

Entry into a Material Definitive Agreement. Underwritten Registered Offering On December 7, 2025, Immix Biopharma, Inc., a Delaware corporation (the “ Company ”), entered into an underwriting agreement (the “ Underwriting Agreement ”) with Morgan Stanley & Co. LLC, as representative of the several underwriters named in Schedule 1 thereto (the “ Underwriters ”), relating to the issuance and sale (the “ Offering ”) of 19,117,646 shares of its common stock, par value $0.0001 per share (the “ Sha…

Unregistered Sales of Equity Securities. The information contained in

Entry into a Material Definitive Agreement. On September 5, 2025, Immix Biopharma, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) and a Registration Rights Agreement (the “Registration Rights Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company sold to the Purchasers in a private placement transaction (the “Private Placement”) (i) 3,831,216 shares (the “Shares”) of the Company’s common stock, p…

Director — Nancy Chang, Ph.D.: Dr. Nancy Chang was appointed as a member of the Board of Directors.

Entry into a Material Definitive Agreement. On June 3, 2025, Immix Biopharma, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “Agreement”) with Citizens JMP Securities, LLC (“Agent”) under which the Company may offer and sell, from time to time at its sole discretion, shares of its $0.0001 par value common stock (“Common Stock”), through the Agent as its sales agent. Pursuant to the Agreement, sales of the Common Stock, if any, will be made under the Company’s effec…

Changes in Registrant’s Certifying Accountant. On May 20, 2024, the partners and professional staff of KMJ Corbin & Company LLP (“KMJ”), which was engaged as the independent registered public accounting firm of Immix Biopharma, Inc. (the “ Company ”), joined Crowe LLP (“ Crowe ”), a public accounting, consulting and technology firm. In connection with this transition, on July 17, 2024, the Company, through and with the approval of its Audit Committee, dismissed KMJ as the Company’s independen…

The filing pertains to stockholder approval of amendments to the equity incentive plan, not a management change.

The offer and sale of the Merger Shares were exempt from registration pursuant to Section 4(a)(2) and/or Rule 506 of Regulation D of the Securities Act of 1933, as amended (the “Securities Act”), since the foregoing offer, sales and issuances did not involve a public offering, the recipients have confirmed that they are “accredited investors”, and the recipients acquired the securities for investment only and not with a view towards, or for resale in connection with, the public sale or distri…

Entry into a Material Definitive Agreement. On February 5, 2024, Immix Biopharma, Inc. (the “Company”) entered into an Underwriting Agreement (the “Agreement”) with Titan Partners Group LLC, a division of American Capital Partners, LLC (the “Underwriter”), relating to an underwritten offering (the “Offering”) of 5,535,055 shares (“Shares”) of common stock of the Company (“Common Stock”). The public offering price is $2.71 per share of Common Stock and the Underwriter has agreed to purchase th…

Other Events. On February 5, 2024, Immix Biopharma, Inc. (the “Company”) suspended, and is not offering any shares of its common stock pursuant to, the prospectus supplement dated July 14, 2023, relating to the Sales Agreement, dated July 14, 2023 (the “Sales Agreement”), by and between the Company and ThinkEquity LLC. The Company will not make any sales of common stock pursuant to the Sales Agreement unless and until a new prospectus supplement is filed with the SEC; however, the Sales Agree…

Entry into a Material Definitive Agreement. On August 21, 2023, Immix Biopharma, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with a certain accredited investor (the “Purchaser”), pursuant to which the Company agreed to sell and issue to the Purchaser in a private placement transaction (the “Private Placement”) (i) 3,241,076 shares (the “Shares”) of the Company’s common stock, par value $0.0001 (“Common Stock”), and (ii) pre-funded wa…

Unregistered Sales of Equity Securities. The information contained in

Director — Yekaterina Chudnovsky: Ms. Yekaterina Chudnovsky was appointed as a new director of the company.

Entry into Material Definitive Agreement. On July 14, 2023, Immix Biopharma, Inc. (the “Company”) entered into an ATM Sales Agreement (the “Sales Agreement”) with ThinkEquity LLC (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), subject to the terms and conditions set forth in the Sales Agreement. The Shares will be offered and…

Entry into Material Definitive Agreement. On March 22, 2023, Immix Biopharma, Inc. (the “Company”) entered into an ATM Sales Agreement (the “Sales Agreement”) with ThinkEquity LLC (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $5,000,000, subject to the terms and conditions set for…

Entry into a Material Definitive Agreement. Immix Biopharma, Inc. informs its investors that neither it nor any of its subsidiaries holds cash deposits or securities at Silvergate Bank or Silicon Valley Bank. The information in this

Entry into a Material Definitive Agreement . On January 12, 2023, Nexcella, Inc. (“Nexcella”), a subsidiary of Immix Biopharma, Inc. (collectively, the “Company”) entered into share purchase agreements (the “Purchase Agreements”) with certain accredited investors for their purchase of an aggregate 100,152 shares of Nexcella’s common stock at a purchase price of $6.49 per share, for gross proceeds of approximately $650,000 (the “Private Placement”). Immediately after the closing of the Private…

Unregistered Sale of Equity Securities. The information set forth in

Entry into a Material Definitive Agreement . On December 8, 2022, Nexcella, Inc. (formerly Immix Biopharma Cell Therapy, Inc.) (“Nexcella”), a wholly-owned subsidiary of Immix Biopharma, Inc. (the “Company”) entered into a Research and License Agreement (the “Agreement”) with Hadasit Medical Research Services & Development, Ltd. and BIRAD Research and Development Company Ltd. (collectively, the “Licensors”) pursuant to which the Licensors granted to Nexcella an exclusive, worldwide, royalty-b…